Poster Presentation Australian Diabetes Society and the Australian Diabetes Educators Association Annual Scientific Meeting 2014

Complications and costs associated with diabetes in pregnancy: a retrospective analysis (#280)

Katherine Davies 1 , Lois Jovanovic 2 , Yuanjie Liang 3 , Wayne Weng 3 , Marianthe Hamilton 3 , Lisa Chen 3 , Neil Wintfeld 3
  1. Novo Nordisk, Baulkham Hills, NSW, Australia
  2. Sansum Diabetes Research Institute, Santa Barbara, CA, USA
  3. Novo Nordisk Inc., Princeton, NJ, USA

The ever-increasing prevalence of diabetes affects a substantial number of pregnant women in the USA. In this retrospective claims analysis, patients were identified from a Truven Health Marketscan database (2004–2011 inclusive) to assess costs and complications for pregnant women with and without diabetes and their newborns. A total of 839,792 women met inclusion criteria (female, aged 18–45 years, with ascertainable diabetes [yes/no] status, birth event date >2005 and continuous health plan enrolment ≥21 months before and 3 months after the birth). Of these, 66,041 (7.86%) had diabetes (type 1 diabetes [T1D] 0.13%; type 2 diabetes [T2D] 1.21%; gestational diabetes [GDM] 6.29%; progressing GDM 0.23%). Although glycaemic control was not assessed, relative risk (RR) of stillbirth was numerically greater in T1D, T2D and progressing GDM; C-section RR was greater in all diabetes types vs. non-diabetes. Excluding unknown outcomes, risk of major congenital (RR: 1.84), major circulatory (RR: 2.75) and overall congenital (RR: 1.42) complications was greater in newborns of mothers with T2D (n=4,166) than without diabetes (n=353,599); mothers with T2D had higher risk of anaemia, hypertension, depression, infection, migraine, cardiac, respiratory or obstetrical complications than those without diabetes. Mean medical costs were higher in women with diabetes, particularly T1D. These data highlight a public health concern and call for optimising diabetes management in pregnancy.

1540-Davies%20table.JPGAcknowledgements: Novo Nordisk sponsored the claims analysis and abstract submission.